The impact of Human Epidermal growth factor Receptor 2 (HER2) expression by RT-PCR on tumor characteristics and outcome in estrogen receptor (ER) positive, HER2 negative early-stage breast cancer

被引：0
|
作者：
Goldvaser, Hadar
Mutai, Raz
Stemmer, Salomon
Kuchuk, Iryna
Tokar, Margarita
Paluch-Shimon, Shani
Yerushalmi, Rinat
Drumea, Karen
Evron, Ella
Sonnenblick, Amir
Gal-Yam, Einav
Bar Sela, Gil
Shai, Ayelet
Merose, Rotem
Bareket-Samish, Avital
Soussan-Gutman, Lior
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO5-01-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO5-01-08
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Trastuzumab A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
    Garnock-Jones, Karly P.
    Keating, Gillian M.
    Scott, Lesley J.
    DRUGS, 2010, 70 (02) : 215 - 239
  • [32] TrastuzumabA Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer
    Karly P. Garnock-Jones
    Gillian M. Keating
    Lesley J. Scott
    Drugs, 2010, 70 : 215 - 239
  • [33] Recent progress in immunotherapy of breast cancer targeting the human epidermal growth factor receptor 2 (HER2)
    Seyedmirzaei, Homa
    Keshavarz-Fathi, Mahsa
    Razi, Sepideh
    Gity, Masoumeh
    Rezaei, Nima
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (05) : 1235 - 1244
  • [34] Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
    Siena, S.
    Sartore-Bianchi, A.
    Marsoni, S.
    Hurwitz, H. I.
    McCall, S. J.
    Penault-Llorca, F.
    Srock, S.
    Bardelli, A.
    Trusolino, L.
    ANNALS OF ONCOLOGY, 2018, 29 (05) : 1108 - 1119
  • [35] An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
    Elshazly, Ahmed M.
    Gewirtz, David A.
    CANCER DRUG RESISTANCE, 2022, 5 (02) : 472 - 486
  • [36] Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer
    Awada, Gil
    Gombos, Andrea
    Aftimos, Philippe
    Awada, Ahmad
    EXPERT OPINION ON EMERGING DRUGS, 2016, 21 (01) : 91 - 101
  • [37] Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges
    Laokulrath, Natthawadee
    Gudi, Mihir
    Salahuddin, Syed Ahmed
    Chong, Angela Phek Yoon
    Ding, Cristine
    Iqbal, Jabed
    Leow, Wei Qiang
    Tan, Benjamin Yongcheng
    Tse, Gary
    Rakha, Emad
    Tan, Puay Hoon
    HISTOPATHOLOGY, 2024, 85 (03) : 371 - 382
  • [38] A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer
    Nixon, N. A.
    Hannouf, M. B.
    Verma, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 89 : 72 - 81
  • [39] Comparison of OncotypeDX Recurrence Scores (RS) and MammaPrint (MP) scores, and chemotherapy indications in early-stage Estrogen Receptor positive/HER2 negative (ER-/HER2-) breast cancer
    Singh, Rishika
    Barlow, William
    Singh, Nupur
    Elliott, James
    Fine, Richard
    Berry, Michael
    Cobain, Erin
    Pusztai, Lajos
    Vidal, Gregory
    CANCER RESEARCH, 2024, 84 (09)
  • [40] Characterization of the tumor microenvironment in patients with hormone receptor positive, HER2 negative early breast cancer
    Kearney, Matthew Ryan
    Vanguri, Rami
    Wang, Qi
    Fenn, Kathleen
    Guo, Hua
    Marks, Douglas
    Hibshoosh, Hanina
    Kalinsky, Kevin M.
    Connolly, Eileen
    CANCER RESEARCH, 2022, 82 (04)
12345